The Patented Medicine Prices Review Board (PMPRB) released its new draft Guidelines and launched a 60-day consultation period with stakeholders and interested members of the public. This consultation follows Health Canada’s recent amendments to the Patented Medicines Regulations, which strengthen and modernize Canada’s pricing framework for patented drugs to better protect Canadian consumers from excessive prices in … Read more
A new Patented Medicine Prices Review Board report reveals that prescription drug expenditures by Canadian public drug plans grew by 7.4 per cent to reach $11.4 billion in 2017-18. Drug costs were up by 8.3 per cent over the previous fiscal year, with expenditures on drugs exceeding $10,000 in annual treatment costs rising by 19.3 per cent. The … Read more
The latest edition of the Patented Medicine Prices Review Board Generics360 report finds that government policies have significantly reduced the prices for generic drugs in recent years, resulting in important savings for Canadians. Over the past decade, the pan-Canadian Pharmaceutical Alliance (pCPA) has made a concerted effort to lower generic drug prices in Canada. The most recent … Read more
Chairperson Dr. Mitchell Levine made the following statement regarding Health Canada’s final amendments to the Patented Medicines Regulations: “With these amendments, the PMPRB now has the tools and information needed to meaningfully protect Canadian consumers from excessive prices today and into the future. We would like to thank the Minister of Health for placing her confidence … Read more
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the 2018 edition of Meds Pipeline Monitor. This annual publication provides a snapshot of the new drug landscape, highlighting medicines currently in clinical trials that may significantly impact future clinical practice and/or drug spending in Canada if and when they … Read more
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the 2017 edition of Meds Entry Watch, an annual publication that provides the latest information on new medicines entering Canadian and international markets. The full release is available online.
The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name Procysbi by the patentee Horizon Therapeutics Canada. Further details on the public hearing and a case management conference will be announced at a later date. The full … Read more
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the latest edition of the Market Intelligence Report: Anti-Vascular Endothelial Growth Factor Drugs for Retinal Conditions, 2017. The full release is available online. Call 613-288-9664.
The Patented Medicine Prices Review Board is seeking applicants for membership on the Board by way of open, transparent, and merit-based Governor in Council selection processes for the positions of Chairperson and Board member. The full release is available online. Call 613-288-9664.
Health Minister Ginette Petitpas Taylor (Moncton–Riverview–Dieppe, N.B.) tabled the 2017 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the House of Commons and the Senate. The full release is available online.
